As of 2026-03-17, the Relative Valuation of Aclaris Therapeutics Inc (ACRS) is (9.19) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.74 USD, the upside of Aclaris Therapeutics Inc based on Relative Valuation is -345.8%.
The range of the Relative Valuation is (8.91) - (9.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 19.0x | 18.0x |
| Forward P/E multiples | 14.7x - 18.5x | 16.2x |
| Fair Price | (8.91) - (9.94) | (9.19) |
| Upside | -338.4% - -365.7% | -345.8% |
| Date | P/E |
| 2026-03-16 | -6.95 |
| 2026-03-13 | -6.58 |
| 2026-03-12 | -6.52 |
| 2026-03-11 | -6.69 |
| 2026-03-10 | -6.82 |
| 2026-03-09 | -6.30 |
| 2026-03-06 | -5.68 |
| 2026-03-05 | -5.80 |
| 2026-03-04 | -5.76 |
| 2026-03-03 | -5.65 |
| 2026-03-02 | -5.67 |
| 2026-02-27 | -5.33 |
| 2026-02-26 | -5.81 |
| 2026-02-25 | -6.15 |
| 2026-02-24 | -6.24 |
| 2026-02-23 | -6.04 |
| 2026-02-20 | -6.02 |
| 2026-02-19 | -6.00 |
| 2026-02-18 | -5.89 |
| 2026-02-17 | -6.06 |
| 2026-02-13 | -5.93 |
| 2026-02-12 | -6.24 |
| 2026-02-11 | -6.30 |
| 2026-02-10 | -6.78 |
| 2026-02-09 | -6.85 |
| 2026-02-06 | -6.63 |
| 2026-02-05 | -6.30 |
| 2026-02-04 | -6.58 |
| 2026-02-03 | -6.45 |
| 2026-02-02 | -6.71 |
| 2026-01-30 | -6.52 |
| 2026-01-29 | -6.37 |
| 2026-01-28 | -6.52 |
| 2026-01-27 | -7.19 |
| 2026-01-26 | -7.10 |
| 2026-01-23 | -8.36 |
| 2026-01-22 | -8.41 |
| 2026-01-21 | -8.21 |
| 2026-01-20 | -8.23 |
| 2026-01-16 | -4.87 |
| 2026-01-15 | -4.96 |
| 2026-01-14 | -5.09 |
| 2026-01-13 | -5.03 |
| 2026-01-12 | -4.94 |
| 2026-01-09 | -4.90 |
| 2026-01-08 | -4.98 |
| 2026-01-07 | -4.98 |
| 2026-01-06 | -4.92 |
| 2026-01-05 | -4.92 |
| 2026-01-02 | -5.35 |